

Market Overview

The first quarter of 2017 experienced the same high valuations and favorable market fundamentals in the contract research space that were observed in 2016. Factors driving merger and acquisition activity include a robust pharma pipeline, a growing proportion of drugs under development attributed to smaller pharmaceutical companies, and an increased focus on the development of biologics and biosimilars. Provident expects the current industry tailwinds to continue to fuel consolidation activity throughout 2017.

SELECT TRANSACTIONS:

Date	Acquirer	Target	Description
March 2017	Bioreclamation IVT	Translational Cell Science	BioreclamationIVT, a worldwide provider of biological products to the life sciences and pharmaceutical industries, acquired Translation Cell Science. Translation Cell Science is a privately held contract research organization specializing in the use of primary cells for phenotypic screening assays. The financial terms of the deal were not disclosed.
March 2017	Genesis Biotechnology Group	PharmOptima	Genesis Biotechnology, a consortium of an integrated group of biotechnology and research companies, acquired PharmOptima. PharmOptima is a contract research organization that provides consulting and laboratory services. The company offers drug discovery by optimizing drug lead identification utilizing compound biochemical mechanisms of action and proof of concept studies. The financial terms of the deal were not disclosed.
February 2017	Quad-C Management	Pharm-Olam International	Quad-C Management, a middle market private equity firm, acquired Pharm-Olam International. Pharm-Olam is a multinational, full-service clinical research organization serving the biopharmaceutical and medical device industries. Based in Houston, Texas, Pharm-Olam has 27 offices worldwide and has supported clinical trials in over 60 countries. The financial terms of the transaction were not disclosed.
January 2017	Porton USA	J-STAR Research	Porton USA, a manufacturer and developer of drug intermediaries, acquired J-STAR Research for \$26 million in cash. J-STAR Research operates as a contract research organization for pharmaceutical and biotechnology companies in the United States and internationally with 47 employees. It offers services in the areas of custom synthesis/contract research, process and analytical research, cGMP synthesis, solid form screening, and crystallization services. The company was founded in 1996 and is based in South Plainfield, New Jersey.
January 2017	WuXi PharmaTech	HD Biosciences	WuXi AppTec, a pharmaceutical, biotechnology and medical device open-access capability and technology platform, acquired HD Biosciences, a biology focused preclinical drug discovery contract research organization. The financial terms of the deal were not disclosed.
January 2017	Phamaron	AMS Sciences	Pharmaron, a R&D service provider for the life sciences industry, acquired AMS Sciences. AMS Sciences provides clinical research services for pharmaceutical and biotechnology companies. The company was founded in 1997 and is based in Germantown, Maryland. The financial terms of the deal were not disclosed.